A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research - Eighteen Million Assays and Counting
A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research - Eighteen Million Assays and Counting
复制标题
DOI：
10.2174/1386207317666140109122450
复制
发表时间：
2014-03-01
影响因子：
1.8
通讯作者：
Street, Ian
中科院分区：
文献类型：
--
作者：
Lackovic, Kurt;Lessene, Guillaume;Street, Ian
Walter and Eliza Hall Institute of Medical Research（WEHI）是澳大利亚历史最悠久的医学研究机构。WEHI的高通量筛选（HTS）设施成立于2003年，由WEHI投资500万美元的基础设施资金，维多利亚州政府的战略技术倡议通过Bio21 Australia Ltd.该设施是澳大利亚第一个真正的学术HTS设施，也是当时世界上少数几个在公共资助机构中运营的设施之一。其目标是提供使用HTS技术的机会，例如检测设计、液体处理自动化、化合物库和专业知识，以促进在生物技术部门相对年轻且没有大型制药研究存在的国家环境中进行基础研究的转化。十年来，WEHI HTS设施参与了超过92个合作项目，产生了超过1800万个数据点，最重要的是，在该设施开始的项目已经成功商业化（由于与业务开发的紧密联系和对知识产权管理的重视），现在已经在临床试验中取得了进展。
The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia's longest serving medical research institute. WEHI's High Throughput Screening (HTS) Facility was established in 2003 with $5 million of infrastructure funds invested by WEHI, and the Victorian State Government's Strategic Technology Initiative through Bio21 Australia Ltd. The Facility was Australia's first truly academic HTS facility and was one of only a handful operating in publicly funded institutions worldwide at that time. The objectives were to provide access to enabling HTS technologies, such as assay design, liquid handling automation, compound libraries and expertise to promote translation of basic research in a national setting that has a relatively young biotech sector and does not have a big Pharma research presence. Ten years on and the WEHI HTS Facility has participated in over 92 collaborative projects, generated over 18 million data points, and most importantly, projects that began in the Facility have been commercialized successfully (due to strong ties with Business Development and emphasis on intellectual property management) and now have molecules progressing in clinical trials.